Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 4, 2010, Pages 385-390

  Van Tassell, Benjamin W ^a   Seropian, Ignacio M ^a   Toldo, Stefano ^a   Salloum, Fadi N ^a   Smithson, Lisa ^a   Varma, Amit ^a   Hoke, Nicholas N ^a   Gelwix, Christopher ^a   Chau, Vinh ^a   Abbate, Antonio ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Acute myocardial infarction; Heart failure; Inflammation; MyD88

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; IMG 2005; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; SMALL INTERFERING RNA; ST 2825; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS; INTERLEUKIN 1BETA; MYD88 PROTEIN, MOUSE; SPIRO COMPOUND; ST2825;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMEGALY; CONTROLLED STUDY; DRUG TARGETING; ECHOCARDIOGRAPHY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; GENETICS; HEART; HEART MUSCLE; HEART VENTRICLE; HEART VENTRICLE REMODELING; HYPERTROPHY, LEFT VENTRICULAR; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY;

ANIMALS; HEART; HEART VENTRICLES; HETEROCYCLIC COMPOUNDS, 2-RING; HYPERTROPHY, LEFT VENTRICULAR; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICE; MICE, INBRED ICR; MYELOID DIFFERENTIATION FACTOR 88; MYOCARDIAL INFARCTION; MYOCARDIUM; NF-KAPPA B; RNA, SMALL INTERFERING; SPIRO COMPOUNDS; VENTRICULAR REMODELING;

EID: 77951738048     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181d3da24     Document Type: Article

References (32)

1. National Heart Lung and Blood Institute. Morbidity and Mortality: 2007 Chart Book on Cardiovascular and Lung Diseases. Bethesda, MD: NIH; 2007.
2. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281-292.
3. Abbate A, Kontos MC, Biondi-Zoccai GG. No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction. Eur Heart J. 2008;29:1795-1797.
4. Frangogiannis N. The immune system and cardiac repair. Pharm Res. 2008;58:88-111.
5. Abbate A, Bussani R, Amin MS, et al. Acute myocardial infarction and heart failure: role of apoptosis. Int J Biochem Cell Biol. 2006;38:1834-1840.
6. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95(Suppl):9C-16C.
7. Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental myocardial infarction. Circulation. 2008;117:2670-2683.
8. Bujak M, Dobaczewski M, Chatila K, et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol. 2008;173:57-67.
9. Venkatachalam K, Prabhu SD, Reddy VS, et al. Neutralization of Interleukin-18 ameliorates ischemia/reperfusion induced myocardial injury. J Biol Chem. 2009;284:7853-7865
10. Yu Q, Vasquez R, Khojeini EV, et al. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol. 2009;297:H76-H85.
11. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-1549.
12. Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008;52:2166-2174.
13. Riad A, Jagar S, Sobirey M, et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol. 2008;180:6954-6961.
14. Shishido T, Nozaki N, Yamaguchi S, et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation. 2003; 108:2905-2910.
15. Kim SC, Ghanem A, Stapel H, et al. Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol. 2007;7:5-14.
16. O'Neil LAJ, Bowie AG. The family of five: TIR-domain-containing adaptors inToll-like receptor signaling. Nat Rev Immunol. 2007;7:353-364.
17. Daun JM, Fenton MJ. Interleukin-1/Toll receptor family members: receptor structure and signal transduction pathways. J Interf Cytokine Res. 2000;20:843-857.
18. Feng Y, Zhao H, Xu X, et al. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol. 2008;295:H1311-H1318.
19. Hua F, Ha T, Ma J, Gao X, et al. Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts. Biochem Biophys Res Commun. 2005;338:1118-1125.
20. Maekawa Y, Mizui N, Chan A, et al. Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune Interleukin-1 receptor-associated kinase-4 signaling. A regulator of bone marrow-derived dendritic cells. Circulation. 2009. [Epub ahead of print].
21. Loiarro M, Capolunghi F, Fantò N, et al. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007;82:801-810.
22. Loiarro M, Sette C, Gallo G, et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1 dependent activation of NF-kB. J Biol Chem. 2005;280:15809-15814.
23. Derossi D, Joliot AH, Chassaings G. The third helix of the antennapedia homeodomain translocates through biological membranes. J Biol Chem. 1994;269:10444-10450.
24. Natarajan R, Salloum FN, Fisher BJ, et al. Hypoxia inducible factor-1 activation by prolyl4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res. 2006;98:133-140.
25. Parikh AA, Salzman AL, Kane CD, et al. IL-6 production in human intestinal epithelial cells following stimulation with IL-1 beta is associated with activation of the transcription factor NF-kappa B. J Surg Res. 1997; 69:139-144.
26. Gardin J, Adams D, Douglas P, et al. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr. 2002;15:275-290. (Pubitemid 44970067)
27. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569-582.
28. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;29:44-51.
29. Gilroy DW, Lawrence T, Perretti M, et al. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov. 2004;3:401-416.
30. Vandervelde S, van Amerongen MJ, Tio RA, et al. Increased inflammatory response and neorevascularization in reperfused vs nonreperfused murine myocardial infarction. Cardiovasc Pathol. 2006;16:83-90.
31. Cintron G, Johnson G, Francis G, et al. Prognostic significance of serial changes in left ventricular ejection fraction in patients with heart failure. The V-HeFT VA Cooperative studies group. Circulation. 1993;87:V-117- V-123.
32. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol. 2002;39:1414-1421